Introduction: Primary pulmonary lymphoepithelioma-like carcinoma (LELC) is a histologically distinctive subtype of NSCLC and an Epstein-Barr virus (EBV)-associated epithelial neoplasm. We investigated the clinical significance of plasma concentrations of EBV DNA in patients with pulmonary LELC.
Introduction
Primary lymphoepithelioma-like carcinoma (LELC), which was first described by Bégin et al. in 1987 , has been recognized as a rare but distinctive histologic variant among undifferentiated carcinomas that is histologically identical to lymphoepithelioma carcinomas arising in the nasopharynx and in other anatomic sites. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Of particular interest is the close association between Epstein-Barr virus (EBV) infection and the occurrence of pulmonary LELC in Asian patients. 15, 16 Compared with patients with other types of NSCLC, patients with pulmonary LELC have a significantly better prognosis. [17] [18] [19] The mean age of patients with LELC is 10 years younger than that of the patients with other histologic types of NSCLC. In contrast to other lung carcinomas, LELC tends to affect nonsmokers more frequently. Most patients with LELC of the lung have early-stage disease at their initial examination. 3, 13, 14 The etiologic and molecular events responsible for occurrence of these tumors are almost entirely unknown.
Cell-free EBV DNA can be found in the plasma of patients with pulmonary LELC. Prior investigation has demonstrated an association between circulating EBV DNA and overall survival (OS) of pulmonary LELC. 15, 20 We hypothesized that plasma EBV DNA measured at baseline may have prognostic significance and may predict for recurrence and disease progression. This study was undertaken to evaluate the association between baseline EBV DNA and OS and disease-free survival (DFS) in prospectively collected plasma samples from a multicenter rare lung cancer study in Southern China. In addition, exploratory analyses evaluated the significance of changes in EBV DNA levels in patients with advanced-stage pulmonary LELC.
Materials and Methods

Study Population
Patients with stage I to stage IV pulmonary LELC who had follow-up data and adequate blood samples for EBV DNA measurement were enrolled between May 2010 and December 2015 as an initial cohort at Sun Yat-sen University Cancer Center, The First Affiliated Hospital of Guangzhou Medical University, and the Cancer Center of Guangzhou Medical University.
To examine the generalizability of the model, a confirmatory cohort consisted of patients treated between January 2011 and June 2016 at Guangdong General Hospital and The First Affiliated Hospital of Sun Yat-sen University. Standardized clinical data for all patients treated in each of the five institutions were entered into an independent central database.
Follow-up data for all patients were obtained from medical review and a telephone interview that consisted of a systemic clinical examination and an assessment of computed tomography scans. Patients were excluded if they had received neoadjuvant therapy without pretreatment blood samples or secondary primary cancer. An independent biostatistician managed and maintained the collected data. All patients provided written informed consent for collection of blood and clinical follow-up information. Ethical approval was obtained from participating institutions through their respective institutional review boards (at The First Affiliated Hospital of Guangzhou Medical University, Cancer Center of Guangzhou Medical University, and The First Affiliated Hospital of Sun Yat-sen University).
DNA Extraction from Serum Samples
Blood samples were prospectively collected from all study participants at the time of diagnosis. During the follow-up period, blood samples were collected 3 months after radical resection (stage I to stage IIIA). Sequential blood draws (before treatment and within 3 months of therapy) were performed to evaluate response to treatment and progression of disease in 68 patients with advanced LELC (stage IIIB and stage IV) who received local or systemic salvage therapy. The following persons were recruited to serve as controls: 50 healthy volunteers and 50 patients with stage IV non-LELC lung cancer.
Peripheral blood (5 mL) was obtained from each patient and control, placed in an ethylenediaminetetraacetic acid tube, and centrifuged at 3000 g for 10 minutes, after which the plasma was transferred into 1.5-mL microtubes. The plasma samples were separated and stored at -80 C. Plasma DNA was extracted with a QIAamp DNA Mini Kit (Qiagen, Valencia, CA). A total of 400 mL per column was used for DNA extraction. The extract amount was documented for calculation of the targeted DNA concentration. Distilled water (50 mL) was used to elute the DNA from the extraction column.
Real-time qPCR for EBV DNA Detection
A real-time quantitative polymerase chain reaction (qPCR) system was developed for plasma EBV DNA detection toward the BamHI-W region. The sequences of the forward and reverse primers were 5 0 -AGT CTC TGC CTC AGG GCA-3 0 and 5 0 -ACA GAG GGC CTG TCC ACCG-3 0 , respectively. A dual fluorescence-labeled
0 , served as a probe. Sequence data for the EBV genome were obtained from the GeneBank sequence data base (accession number V01555). 21 In this study, qPCR for the b-actin gene was used as a control for the amplifiability of plasma DNA. The 
Genetic Analysis
EGFR mutation and KRAS mutation were detected using PCR-based direct sequencing. Briefly, genomic DNA was extracted from tumors embedded in paraffin blocks. PCR amplification was done using HotStarTaq DNA polymerase (Qiagen) by using specific primers. PCR products were sequenced directly using the Applied Biosystems PRISM dye terminator cycle sequencing method (Perkin-Elmer Corp., Foster City, CA) with the ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). ALK receptor tyrosine kinase gene (ALK) rearrangements were detected by fluorescence in situ hybridization (FISH) using a break-apart probe to the ALK gene (Vysis LSI ALK Dual Color, Break Apart Rearrangement Probe, Abbott Molecular, Des Plaines, IL) per the manufacturer's instructions. At least 100 representative tumor cells were counted and then analyzed by using an Olympus fluorescence microscope equipped with orange, green, and 4 0 ,6-diamidino-2-phenylindole filters. Images were captured using the Video Test Image Analysis System. FISH-positive cases were defined as having at least 15% of the tumor cells show a split red and green signal and/or an isolated (single) red signal. Otherwise, the specimen was classified as ALK FISHnegative.
In Situ Hybridization of EBV-Encoded RNA
In situ hybridization was performed on formalinfixed, paraffin-embedded tissue sections by using a fluorescein-conjugated EBV (EBER) RNA probe (Dako, Carpinteria, CA), which is complementary to the two nuclear EBER RNAs encoded by the EBV. According to the manufacturer's instructions, briefly, 4-mm sections were deparaffinized and digested with proteinase K. After the probe was added and incubated at 55 C for 1.5 hours, the sections were washed with astringent solution. A chromogen, 5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt and nitroblue tetrazolium chloride, was then added and counterstained with hematoxylin.
Statistical Analysis
To compare the distribution of characteristics between the initial and confirmatory data sets, we performed c 2 (categorical factors) and Wilcoxon tests (continuous variables). We applied analysis of variance for correlation between log-transformed EB DNA copies and variables. The distribution of plasma EBV DNA data in the initial and confirmatory data sets were skewed, but it was symmetric after log-transformation. To evaluate the potential association of EBV DNA copies with disease response or progression in individual patients, we examined the relationship between changes in raw EBV DNA copies and changes in disease status between two sequential blood draws by using nonparametric tests in patients with advanced-stage LELC. The Kruskal-Wallis test was used for variables with three groups. We postulated that a high level of baseline EBV DNA would lead to a 2.5-fold to threefold increase in hazard ratio (HR) compared with a low level of baseline EBV DNA. We would need to observe about 160 events to have 80% power of detecting this effect with a two-sided test at a level of 5%. OS and DFS was calculated from the time of diagnosis to patient death or last contact or to disease recurrence, respectively. Patients were classified as having recurrence if they had subsequent local, regional nodal, or distant metastasis during follow-up. Individuals lost to follow-up were censored at last date of contact (3% for reasons other than death). Follow-up was active, with a median time of 4.5 years; March 28, 2017, was the censoring date. OS and progression-free survival were estimated by the Kaplan-Meier method. The log-rank test was used to calculate p values. Multivariable analysis was performed by using Cox proportional hazards analysis with a stepdown procedure. Statistical analysis was performed with SPSS 19.0 for Windows software (IBM Corp, Armonk, NY), where p values less than 0.05 were considered significant. Results are reported according to the Reporting Recommendations for Tumor Marker Prognostic Studies guidelines. 22 
Results
Baseline Characteristics of Patients with Pulmonary LELC in the Data Sets
A total of 438 patients with pulmonary LELC were enrolled between May 2010 and June 2016. Excluding six patients with synchronous carcinoma, three patients received neoadjuvant therapy without baseline blood samples, and a total of 429 patients were eligible for analysis ( Supplementary Fig. 1 ). The 287 samples in the initial data set represented patients with sufficient plasma samples collected from Sun Yat-sen University Cancer Center, The First Affiliated Hospital of Guangzhou Medical University, and the Cancer Center of Guangzhou Medical University. The median follow-up time was 4.6 years (range 0.8 to 6.3 years). The median survival time was 4.9 years in the initial cohort. The 142 samples in the confirmatory data set were tested for EBV DNA concentration from Guangdong General Hospital and The First Affiliated Hospital of Sun Yat-sen University after analysis of the initial data set (see Supplementary Fig. 1 ). Median followup time was 4.3 years (range 0.6-5.9 years). The median survival time was 4.7 years in the confirmatory cohort.
Baseline characteristics of the 429 study participants are listed in Table 1 . Compared with patients in the initial data set, patients in the confirmatory data set had a younger median age (p ¼ 0.029) and less history of nonsmoking (p ¼ 0.02) but a higher proportion of advanced tumor stage (p ¼ 0.012) and higher rate of lymphovascular invasion (p ¼ 0.036). The mutation rate of the EGFR gene was 0.7% (two of 287) in the initial data set. No EGFR mutation was detected in the confirmatory data set. No ALK rearrangements or KRAS mutations were detected in the initial data set or confirmatory data set. Positive signals by in situ hybridization for EBER were identified in all pulmonary LELC tissue samples.
EBV DNA was detected in plasma samples from 77 of 77 patients with stage IV pulmonary LELC, but in none of the plasma samples from the 50 patients with non-LELC lung cancer or the 50 healthy volunteers (Supplementary Fig. 2 ). Table 2) .
EBV DNA as a Risk Factor for OS and DFS
To evaluate for a dose effect of raw EBV DNA concentration on OS, we divided baseline EBV DNA concentration into quintiles. Patients in the highest quintile, as compared with patients in the lowest quintile, had a significantly poorer OS (HR ¼ 3.09, 95% confidence interval [CI]: 2.03-4.16, p < 0.001) (Supplementary Table 1 ).
To determine the most appropriate EBV DNA copy number cutoff, a series of baseline EBV DNA copy values between 200 and 122,900 copies/mL (the median and 75th percentile levels of pretreatment EBV DNA concentration were 3700 copies/mL and 12,800 copies/mL, respectively) were tested for their estimate of survival by using the Kaplan-Meier method. After Bonferroni correction for multiple testing, 4000 copies/mL showed the most significant discrimination in survival estimation ( Supplementary Fig. 3 and Supplementary Table 2) . Receiver operating characteristic curves were analyzed, confirming 4000 copies/mL as the optimal cutoff (Supplementary Table 3 and Supplementary Fig. 4 (Table 4) .
Compared with EBV DNA copy values less than 4000 copies/mL, EBV DNA copy values of at least 4000 copies/mL were associated with poorer OS in patients with any-stage (p < 0.001), stage I/II (p < 0.001), or stage III/IV (p < 0.001) disease (Fig. 1A-C) . EBV DNA copy values of at least 4000 copies/mL were also associated with poorer DFS in patients with stage I/II disease (p < 0.001) (Fig. 1D ). Blood samples were collected 3 months after radical resection from patients with stage I to stage IIIA pulmonary LELC (n ¼ 309). The median EBV DNA concentration decreased to zero copies/mL (interquartile range 0-0) 3 months after radical resection. Of these 309 patients, 248 had an undetectable EBV DNA concentration and 61 had a detectable concentration of EBV DNA in their plasma at that time (median 600 copies/mL, range 100-2100). Patients with persistently detectable plasma EBV DNA after radical resection had significantly worse OS (p < 0.001) ( Fig. 2A) and DFS (p < 0.001) (Fig. 2B ) than those with undetectable EBV DNA after surgery.
Correlation of Sequential EBV DNA Copy Values with Disease Burden
To evaluate whether increased EBV DNA copy values were associated with progression in individual patients, change in EBV DNA copy values was compared with change in clinical status in 68 patients with advanced pulmonary LELC (stage IIIB and stage IV) for whom sequential blood samples were available (Supplementary Table 4 ). Supplementary Table 5 summarizes correlations between change in EBV DNA copy values and several alternative measures of disease progression: response to treatment (stable, response, or progression), increase in cancer stage (no increase versus increase), and increase in number of metastases (no increase, one additional metastasis, or more than one additional metastasis). Response to treatment (p < 0.001), increase in cancer stage (p < 0.001), and increase in number of metastases (p < 0.001) were all highly associated with change in EBV DNA copy values.
Discussion
Primary LELC of the lung is a histologically distinctive neoplasm of uncertain tumorigenesis. As in LELC of the nasopharynx, a strong association with EBV has also been reported in LELC of the lung. Increased serum titers of EBV viral capsid antigen immunoglobulin A and EBV viral capsid antigen immunoglobulin G and positive EBV-encoded RNA (EBER) staining in tumor cells by in situ hybridization (ISH) together with circulating EBV DNA lent further support to the virus-cancer association in pulmonary LELC. 7 We previously reported that positive signals by in situ hybridization for EBER were identified in all resected pulmonary LELC samples. 23 Pulmonary LELC occurring in Asian patients almost invariably harbors EBV. The demonstration of clonal episomal EBV in the tumor tissue proved the postulation that EBV infection precedes the clonal expansion of the tumor. 10 The evidence of such an intimate relationship between LELC and EBV further incriminates EBV as a major player in tumorigenesis. Capitalizing on such a relationship, the plasma or serum EBV DNA, which may reflect the tumor burden, can be used as a surrogate tumor marker to assess treatment response and prognosis.
A possible role of the free circulating EBV DNA in nasopharyngeal carcinoma in prognostication, prediction of recurrence, and monitoring therapy response has been suggested. [24] [25] [26] [27] It may also have a role in monitoring response in some lymphomas. 28, 29 EBV DNA has also been found in the serum of patients with EBVassociated gastric cancer. 30, 31 Cell-free EBV DNA can be found in the plasma of patients with pulmonary LELC. It has further been shown that circulating EBV DNA in the plasma of patients with pulmonary LELC has opened up new possibilities for detecting and monitoring this distinctive disease in Asia population. Over the past two decades, only two small studies enrolling 19 patients with advanced pulmonary LELC have been performed to investigate free circulating EBV DNA and suggested its use for monitoring response to therapy. 15, 20 A total of 429 patients with previously untreated pulmonary LELC, mostly stage I to stage III, were enrolled in our study. We performed Kaplan-Meier analysis and Bonferroni correction for multiple testing of the entire pool of patients and found that the best cutoff value of baseline EBV DNA copy was 4000 copies/mL, which is close to a commonly used clinical cutoff value for nasopharyngeal carcinoma. 26 Our stratification analysis determined that baseline EBV DNA copy of at least 4000 copies/mL predicted poorer survival among patients with pulmonary LELC at any-stage and a higher rate of recurrence among those with early-stage disease. Ngan et al. reported results similar to ours, but they used a pretreatment cutoff value of 10,000 copies/mL, which was higher than ours. 20 There are two potential applications of free circulating EBV DNA as a surrogate tumor marker in patients with LELC of the lung; monitoring for OS or relapse after initial therapy is the first important application. In this study, we found that an increased EBV DNA copy value independently predicted disease recurrence and poorer survival among patients with early-or advanced-stage pulmonary LELC. We observed a dose effect between EBV DNA copy values and survival.
In our study in which EBV DNA concentrations were detected for 429 patients with pulmonary LELC, we found an association between plasma EBV DNA level and disease severity; EBV DNA concentration was strongly associated with tumor stage, lymphovascular invasion, and metastasis. We detected an association between increased values of baseline EBV DNA level and OS, with an HR of 3.67. After adjustment for covariates that included standard clinicopathologic predictors of pulmonary LELC progression, this risk was slightly attenuated (to 3.1) but remained significant. Both univariable and multivariable models identified a dose-effect relationship between baseline EBV DNA level and OS.
The second application of serum EBV DNA lies in monitoring for therapy response. Sequential blood draw data in a subset of patients identified associations between EBV DNA copy values and measures of pulmonary LELC disease progression. In analysis of a subset of 68 patients with advanced LELC, we detected strong (although preliminary) correlations between a rise in baseline EBV DNA copy number and disease progression in the individual patient. As plasma EBV DNA frequently preceded disease progression during posttherapy follow-up, it can be used as a sensitive marker to detect subclinical recurrence more amenable to salvage therapy. 20 Moreover, patients with persistently detectable plasma EBV DNA after radical resection had significantly worse OS and DFS than did those with undetectable EBV DNA after surgery. Plasma EBV DNA during therapy or after surgery can also help to monitor therapy response, guide further therapy, and detect early relapse or progression.
Our study has some limitations. Patients with pulmonary LELC were recruited from a population undergoing evaluation at five large hospitals in Sourthern China and might not be representative of the general population with pulmonary LELC. Although a baseline EBV DNA copy level of at least 4000 copies/mL was strongly associated with poorer OS among patients with any-stage disease and poorer DFS among patients with stage I/II disease, we were unable to recruit more patients with pulmonary LELC because of the low incidence of this disease. In addition, because of the multiplicity of treatments provided to patients with advanced disease, and because patients in this study were treated before the widespread of newest targeted therapies or immunotherapy, no attempt was made to adjust for systemic therapies administered. However, we investigated EBV DNA copy levels through two independent cohorts and found that the magnitude of change in EBV DNA copy levels was small; we adjusted for this small effect in our analyses.
Taken together, our results show that plasma EBV DNA concentration can be a useful molecular marker for monitoring and prediction of recurrence and overall survival in patients with pulmonary LELC. Our results and those of previous study cannot yet be considered definitive, however, because the 5-year DFS and OS were 69.4% and 91.4% respectively. 32 
